Krsnaa Diagnostics Limited KRSNAA NSEPHARMA
Company Overview
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.
Why Investors Should Care
Net profit has compounded at 17.8% per year over the last five years.
Revenue has grown at a 16.6% CAGR over the past five years.
Trades at a P/E of 18.1, below the sector median of 41.6.
Operating margin of 15.7% supports profitability.
Recent Developments
- Mar 2026 Revenue of ₹772.77 Cr (+7.8% YoY); net profit ₹101.43 Cr.
- Trailing 12 Months Year-on-year growth — revenue +7.8%, earnings +30.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.6%, profit CAGR 17.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.63% |
| 1 Year: | 7.75% |
Compounded Profit Growth
| 5 Years: | 17.76% |
| 1 Year: | 30.70% |
Stock Price Performance
| 1 Year: | -30.12% |
| 6 Months: | -8.28% |
| 3 Months: | +2.87% |
| 1 Month: | +0.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.20 · Neutral
P/E of 18.13 is below the sector median of 41.64 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.6% over 5 years.
- Profit CAGR of 17.8% over 5 years.
CONS
- Trading 35.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KRSNAA Krsnaa Diagnostics Limited NSEPHARMA | 560.00 | 18.13 | ₹1,816.57 Cr | 0.49% | 10.64% | 10.35% | 16.63% | 17.76% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 133.00 Cr | 140.00 Cr | 155.00 Cr | 158.00 Cr | 166.00 Cr | 170.00 Cr | 186.00 Cr | 175.00 Cr | 186.08 Cr | 192.98 Cr | 205.99 Cr | 181.20 Cr | 192.60 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 58.95 Cr | 62.79 Cr | 65.14 Cr | 54.14 Cr | 58.68 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 127.12 Cr | 130.19 Cr | 140.85 Cr | 127.06 Cr | 133.93 Cr |
| Operating Expenses | 99.00 Cr | 108.00 Cr | 124.00 Cr | 121.00 Cr | 123.00 Cr | 128.00 Cr | 137.00 Cr | 129.00 Cr | 96.09 Cr | 100.42 Cr | 105.28 Cr | 103.28 Cr | 101.64 Cr |
| Operating Income | 19.00 Cr | 15.00 Cr | 13.00 Cr | 16.00 Cr | 26.00 Cr | 22.00 Cr | 27.00 Cr | 22.00 Cr | 31.03 Cr | 29.76 Cr | 35.57 Cr | 23.79 Cr | 32.29 Cr |
| EBITDA | 34.00 Cr | 31.00 Cr | 32.00 Cr | 37.00 Cr | 44.00 Cr | 43.00 Cr | 49.00 Cr | 45.00 Cr | 57.37 Cr | 55.35 Cr | 63.34 Cr | 50.13 Cr | 86.37 Cr |
| Interest Expense | 2.00 Cr | 2.00 Cr | 3.00 Cr | 4.00 Cr | 7.00 Cr | 5.00 Cr | 6.00 Cr | 6.00 Cr | 6.81 Cr | 6.30 Cr | 8.19 Cr | 7.79 Cr | 12.08 Cr |
| Pretax Income | 24.00 Cr | 18.00 Cr | 13.00 Cr | 16.00 Cr | 23.00 Cr | 23.00 Cr | 25.00 Cr | 25.00 Cr | 28.61 Cr | 27.42 Cr | 31.56 Cr | 19.68 Cr | 51.70 Cr |
| Tax Provision | 4.80 Cr | 3.24 Cr | 2.86 Cr | 3.04 Cr | 3.91 Cr | 5.29 Cr | 5.75 Cr | 6.00 Cr | 7.93 Cr | 6.90 Cr | 7.62 Cr | 4.44 Cr | 9.98 Cr |
| Net Income | 19.00 Cr | 15.00 Cr | 10.00 Cr | 13.00 Cr | 19.00 Cr | 18.00 Cr | 20.00 Cr | 19.00 Cr | 20.68 Cr | 20.52 Cr | 23.95 Cr | 15.25 Cr | 41.72 Cr |
| Diluted EPS | 6.03 | 4.66 | 3.34 | 4.02 | 5.80 | 5.55 | 6.07 | 6.01 | 6.28 | 6.25 | 7.25 | 4.66 | 12.70 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 39.00 Cr | 61.00 Cr | - | 487.12 Cr | 619.63 Cr | 717.16 Cr | 772.77 Cr |
| Cost of Revenue | - | - | - | 155.39 Cr | 206.51 Cr | 229.94 Cr | 240.75 Cr |
| Gross Profit | - | - | - | 331.74 Cr | 413.12 Cr | 487.22 Cr | 532.02 Cr |
| Operating Expenses | 30.00 Cr | 42.00 Cr | - | 262.50 Cr | 343.37 Cr | 385.42 Cr | 410.61 Cr |
| Operating Income | 3.00 Cr | 7.00 Cr | - | 69.24 Cr | 69.75 Cr | 101.80 Cr | 121.41 Cr |
| EBITDA | 9.00 Cr | 19.00 Cr | - | 140.42 Cr | 158.64 Cr | 215.66 Cr | 255.19 Cr |
| Interest Expense | 9.00 Cr | 9.00 Cr | - | 6.43 Cr | 14.09 Cr | 24.65 Cr | 34.36 Cr |
| Pretax Income | -3.00 Cr | 0 | - | 80.20 Cr | 70.01 Cr | 102.69 Cr | 130.37 Cr |
| Tax Provision | -1.47 Cr | 0 | - | 18.09 Cr | 13.17 Cr | 25.08 Cr | 28.94 Cr |
| Net Income | -5.00 Cr | -0 | - | 62.11 Cr | 56.84 Cr | 77.61 Cr | 101.43 Cr |
| Diluted EPS | -9.53 | -0.14 | - | 19.29 | 17.31 | 23.56 | 30.88 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | 186.00 Cr | 192.00 Cr | - | 909.89 Cr | 1,171.91 Cr | 1,281.60 Cr | 1,823.72 Cr |
| Current Assets | - | - | - | 222.91 Cr | 421.19 Cr | 414.47 Cr | 738.34 Cr |
| Cash & Equivalents | - | - | - | 22.72 Cr | 2.38 Cr | 3.85 Cr | 30.22 Cr |
| Inventory | - | - | - | 25.07 Cr | 35.81 Cr | 29.48 Cr | 26.66 Cr |
| Receivables | - | - | - | 73.10 Cr | 176.29 Cr | 277.75 Cr | 295.51 Cr |
| Total Liabilities | - | - | - | 171.16 Cr | 362.11 Cr | 398.82 Cr | 843.33 Cr |
| Current Liabilities | - | - | - | 99.19 Cr | 281.47 Cr | 305.39 Cr | 275.20 Cr |
| Long Term Debt | - | - | - | 11.00 Cr | 5.50 Cr | 18.50 Cr | 437.14 Cr |
| Total Debt | 131.00 Cr | 102.00 Cr | - | 32.48 Cr | 159.79 Cr | 203.53 Cr | 534.32 Cr |
| Total Equity | 11.00 Cr | 11.00 Cr | - | 738.74 Cr | 809.80 Cr | 882.77 Cr | 980.39 Cr |
| Shares Outstanding | - | - | - | 3.14 Cr | 3.23 Cr | 3.23 Cr | 3.24 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.00 Cr | 64.00 Cr | - | 76.30 Cr | 24.34 Cr | 87.33 Cr | 143.10 Cr |
| Investing Cash Flow | -47.00 Cr | -54.00 Cr | - | -108.89 Cr | -128.88 Cr | -99.61 Cr | -395.99 Cr |
| Financing Cash Flow | 105.00 Cr | -41.00 Cr | - | -33.15 Cr | 84.19 Cr | 13.75 Cr | 279.26 Cr |
| Capital Expenditure | -46.00 Cr | -54.00 Cr | - | -141.36 Cr | -193.89 Cr | -126.63 Cr | -219.26 Cr |
| Free Cash Flow | -69.00 Cr | 10.00 Cr | - | -65.06 Cr | -169.54 Cr | -39.30 Cr | -76.16 Cr |
| Net Change in Cash | 36.00 Cr | -31.00 Cr | - | -65.73 Cr | -20.34 Cr | 1.47 Cr | 26.38 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 68.1% | 66.7% | 67.9% | 68.8% |
| Operating Margin % | 7.7% | 11.5% | - | 14.2% | 11.3% | 14.2% | 15.7% |
| Net Margin % | -12.8% | -0.0% | - | 12.8% | 9.2% | 10.8% | 13.1% |
| ROE % | -45.5% | -0.0% | - | 8.4% | 7.0% | 8.8% | 10.3% |
| ROCE % | - | - | - | 8.5% | 7.8% | 10.4% | 7.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KRSNAA
Krsnaa Diagnostics sets 16th AGM for September 28, 2026 - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZWlxTVRDc2ltUkVwaEZGdkx0d055c0FRWkhrMG5JZEJ3eklldm9td2oxZUlma3JGOTRHQ2xQc21aaUl1SFF1bWVyME94QzBEeHFMd1BnWGExU1V3RktCSndHbGRFaGl5aVQyek1Sbm5HWnVsN1lXdkxqUGpraTh1cXIweXVxUVV3Q203OU…
Earnings Miss: Krsnaa Diagnostics Limited Missed EPS By 18% And Analysts Are Revising Their Forecasts - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPYXFKNktmSUVES09qa0FfRGhBT1Z5SS1XNlNRVWwxalNmams3RjBUS3JZekZzQTJ4bWFVRDhwblpyRVBnZ2NuR0hEbkt3djJQZ2pPNlhubG16Unl1eXF4MS1lMG82dWVzdjJsUzVtUkxnNGIzSU13SkR2TnE5bzRVNEFqdHpOOUpvTGllZ0…
Earnings call transcript: Krsnaa Diagnostics posts 22% revenue growth in Q1 2026 - Investing.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQQ0tVQmQwb3I4amoyc3NCMzZRNlhkRXBxb1FSNkdud1hoXzJqczZMbHc1SGdkdElKZmpJeDBOYXVyaG8zLXBYOWRHOTBUTGJWVEV5UzRJS01CLXlGODYySWlrWnk1eVVYZUEzc0U1czNmSHFBZ1lxbTZfWDZlekc1bmxaenltdEdSd0NESG…
Krsnaa Diagnostics Ltd. Peer Comparison – Compare with Others - Value Research
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOUy1LV0lwOFpxZXNGM2YxNVRiZS1EajZSNzloOG54Z3NFaHJCUkY1TnFLZEpPY0tGN0JKcW5QRGJWZnJiZW8wZ081OHRwYzIyM1loVFBPc2Q4QUZja0ljd1RFckpnTVNQcFlwa2RwdUtkZmZJdGxHNklfQnNabUItb0ZPWGZ6WEEtWFBrN2…
Krsnaa Diagnostics (KRSNAA.NS) Dips 1.84% to ₹553.65: Key Support at ₹525.97 in Focus - Merger Arbitrage - siam.in
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSGh2NDFkVU90OTJ0bHJWY24xVVhJQWpYQzhtVzZEY1Vna2hkX3FOMTUwVTVtV3NkYV9DTTZwWmVxeFZCSXRQT3ZiS2tESXQ3VGQ1SUpCbTFDRHpuaHlYRHlpdTNjbVhQeDE3T2xDVnctODRVZTZ5WXlpODQtbTdtQkVIZGJMYXc5dlZMWl…
Krsnaa Diagnostics files FY26 BRSR report detailing ESG metrics - scanx.trade
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQVVM1TVVxTDBWNVg2dk1qdHBVdTlCalhQU3JheWVDc1RHVC1ONHhnNlZHRjc3SWpDNWRTSlRWNTFDc1NaUDBVWmQ5TlVMNWhxNEh4SW1sQUs0b2xmTVcxU1NhUkZFREdmNS1TMmYwUXZUY0hxNWR4WjhfeDJ3ZE9QVEhHSU1QZWQxRzlpdD…
KRSNAA — Frequently Asked Questions
What is the current share price of Krsnaa Diagnostics Limited (KRSNAA)?
As of 2026-09-08 04:53 IST, Krsnaa Diagnostics Limited (KRSNAA) trades at ₹560.00 on NSE. Its 52-week range is ₹520.30 to ₹866.20.
What is the market capitalisation of KRSNAA?
Krsnaa Diagnostics Limited (KRSNAA) has a market capitalisation of ₹1,816.57 Cr on NSE.
What is the P/E ratio of KRSNAA?
KRSNAA trades at a trailing price-to-earnings (P/E) ratio of 18.13. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.86.
Does KRSNAA pay a dividend?
Krsnaa Diagnostics Limited (KRSNAA) currently offers a dividend yield of 0.49%.
What is the return on equity (ROE) of KRSNAA?
KRSNAA has a return on equity (ROE) of 10.35%. Its return on capital employed (ROCE) is 10.64%.
Is KRSNAA a good stock to buy?
This page provides a data-driven analysis of Krsnaa Diagnostics Limited (KRSNAA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.